Navigation Links
Genomic Health Announces Year-End 2012 Financial Results, Provides 2013 Financial Outlook
Date:2/6/2013

r long-term growth; the company's intent to invest in its business, the areas of investment and the expected results of those investments; the success or results of clinical trials and the timing of such activities; the applicability of clinical study results to actual outcomes; the ability of the company's tests to impact clinical practice; and the focus and attributes of the company's product pipeline. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: completion of the audit of the company's 2012 financial results; risks related to the commercial launch of a new test for prostate cancer; the company's ability to increase usage of its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the company's success retaining current contracts or levels of reimbursement coverage for its tests; the risks and uncertainties associated with regulation of the company's tests by the FDA and other regulatory organizations; the company's ability to compete against third parties; the company's ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; the success of the company's next generation sequencing technology; the company's ability to successfully commercialize its tests outside of the United States; the ability to obtain capital when needed; the company's history of operating losses; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended
'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Empire Genomics Chooses Funakoshi as Japan Distributor
2. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
3. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
4. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
5. Gentris Corporation Launches New Pharmacogenomics Services
6. Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
7. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
8. Elsevier Launches New Open Access Journal: Applied and Translational Genomics
9. Genomic Health to Announce Second Quarter 2012 Financial Results and Host Conference Call on Wednesday, August 8, 2012
10. Genomic Health to Present at the Canaccord Genuity Growth Conference
11. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC ...  filed a Preliminary Proxy Statement, Schedule 14A, with the U.S. ... an update for shareholders detailing why a "YES" vote to ... Dear Shareholders, As we reflect upon the 2014 ...
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Unomedical Inc., a manufacturer of medical devices, today ... certain units of the single-patient use Manual Pulmonary Resuscitator ... 2002 - March 2008 and matching the lot numbers ... http://www.unomedical.com/?pageid=H3160 . This recall is being conducted ...
... a manufacturer of advanced cell imaging systems, today ... ImageStreamX imaging flow cytometers. The new instrument - ... - combines the speed, sensitivity, and phenotyping abilities ... feature set, and functional insights of microscopy. , ...
Cached Medicine Technology:Unomedical Issues Worldwide Recall of Certain Manual Pulmonary Resuscitators 2Amnis Begins Shipment of New ImageStreamX Imaging Flow Cytometers 2
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... 8 The National Business Group on Health, a non-profit ... that Sally Welborn, Senior Vice President of Benefits at Walmart, ... , "We are thrilled to announce Sally,s election to our ... President of Human Resources at Coca-Cola Enterprises Inc. and Chairman ...
... , ... Technologies, Inc. , has been selected by the Blue Cross ... watchlist screening software for OFAC, OIG and EPLS and USA PATRIOT ... compliance software to BCBSA,s Chicago headquarters and its member Blue Cross ...
... , - May Set Stage for Treating Brain Damage ... researchers have shown that feeding amino acids to brain-injured animals restores ... effective treatment for cognitive impairments suffered by people with traumatic brain ... intervention can restore a proper balance of neurochemicals in the injured ...
... levels increase, so does depression, anxiety and panic disorder, ... Young adults with elevated levels of lead in their ... and panic disorders, a new study suggests. , Researchers ... who took part in the U.S. National Health and ...
... is defined as the pathological retrograde movement of ... disturbances which may be important in reflux are ... motility disorder in these patients is ineffective esophageal ... have been shown to be strongly associated with ...
... is unclear whether patients with soft tissue sarcoma can ... type of therapy, some of the patient,s own (autologous) ... generally re-implanted after a course of high-dose chemotherapy. At ... benefit compared to conventional chemotherapy. Owing to current gaps ...
Cached Medicine News:Health News:National Business Group on Health Elects Sally Welborn, Walmart Executive, to Board of Directors 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 3Health News:With Amino Acid Diet, Mice Improve After Brain Injury 2Health News:With Amino Acid Diet, Mice Improve After Brain Injury 3Health News:Lead Exposure May Affect Mental Health 2Health News:Are manometric findings different between the patients with erosive and nonerosive disease? 2Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 2Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 3Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 4
... Optimal canal flare index. A/P and lateral ... rotational stability. Proximal medial hole, humeral / ... joint translation. Rough textured proximal surface to ... rotational resistance in cement, six stem sizes, ...
...
...
The AGC Revision Knee, extends the AGC Family to include implants for severe primary knees or revision. Provides rotational freedom of +/- 2 and varus/valgus freedom of +/- 1.5....
Medicine Products: